Tumor Cell Vaccine Development Solutions

Whole-cell cancer vaccines harness the complete antigenic repertoire of tumor cells to initiate a broad-spectrum immune response. By presenting the immune system with the full array of Tumor-Associated Antigens (TAAs) and neoantigens, these vaccines minimize the risk of tumor escape often seen with single-antigen approaches.

Creative Biolabs offers a premier tumor cell vaccine development solution dedicated to transforming immunologically "cold" tumors into "hot" targets. From autologous cell harvesting to allogeneic cell line engineering and lethal irradiation, we provide end-to-end preclinical services to maximize the immunogenicity of cellular vaccines.

Get a Quote

Addressing Immunogenicity Barriers in Cell Vaccines

While tumor cells contain all relevant antigens, they are naturally selected to evade immune detection. Our development strategies focus on breaking this tolerance mechanism:

▶ Lack of Costimulation: Tumor cells typically lack expression of B7.1/B7.2 molecules, leading to T-cell anergy. We utilize Genetic Modification to ectopically express these critical costimulatory signals.
▶ Weak Antigen Presentation: MHC downregulation is common in tumors. Our Cytokine Engineering strategies (e.g., GM-CSF secretion) recruit professional APCs to the injection site for efficient cross-priming.
▶ Safety & Replication: Live tumor cells pose safety risks. We employ standardized Lethal Irradiation Protocols to ensure cells are replication-incompetent while retaining metabolic activity and antigen expression.
▶ Autoimmunity Risks: Targeting shared antigens can damage healthy tissue. We provide detailed Preclinical Safety Assessments to evaluate potential autoimmune toxicity.

Consult Our Experts

Our Solutions

We provide a comprehensive suite of services to design and manufacture potent whole-cell vaccines for preclinical evaluation:

Autologous Vaccine Preparation

Isolation and expansion of patient-specific tumor cells (from PDX models or biopsy) to create personalized vaccines with a perfect antigenic match.

Allogeneic Cell Line Engineering

Selection and modification of standardized tumor cell lines (e.g., PC-3, LNCaP) to serve as "off-the-shelf" universal vaccines covering common shared antigens.

Haptenization & Lysates

Chemical conjugation of haptens (e.g., DNP) to cell surfaces or generation of viral oncolysates to increase the visibility of tumor antigens to the immune system.

Adjuvant & Formulation

Co-formulation with biological adjuvants (BCG, Corynebacterium) or molecular adjuvants (TLR agonists) to boost the magnitude of the T-cell response.

Specialized Development Services

Creative Biolabs offers specialized modules designed to enhance the potency and applicability of tumor cell vaccines:

Design and Modification of Allogeneic Cell Vaccines

We provide genetic engineering services to transform low-immunogenic tumor cells into potent vaccines. This includes stable transfection to express immunostimulatory cytokines (GM-CSF, IL-12) or costimulatory molecules (B7.1, ICAM-1) on the cell surface.

Learn More →

Hematopoietic Stem Cell Transplantation (HSCT) Platform

Capitalizing on the lymphopenic state post-HSCT, we design vaccination strategies that drive homeostatic proliferation towards tumor reactivity. This platform focuses on vaccinating early after high-dose therapy to skew the regenerating immune system against residual disease.

Learn More →

Costimulatory Molecules Development

We develop novel molecular adjuvants targeting key immune checkpoints and activation pathways. Our services include the integration of ligands for the PD-1/B7-H1/B7-DC and CD137/CD137L pathways directly into the vaccine cell line to orchestrate a superior antitumor response.

Learn More →

Tumor Cell Lysate Preparation

For applications where whole cells are not feasible, we provide high-quality tumor lysates generated via freeze-thaw cycles or UVB irradiation. These lysates are rich in tumor antigens and serve as excellent sources for loading Dendritic Cell (DC) vaccines.

Learn More →

Development Status Assessment

We offer consulting and landscape analysis services for Prostate Cancer and Melanoma whole-cell vaccines. Our reports cover the efficacy of combination therapies (e.g., with chemotherapy or checkpoint inhibitors) to guide your preclinical strategy.

Learn More →

Streamlined Development Workflow

Our established pipeline ensures the consistent production of high-potency cellular vaccines for research use:

Step 1: Cell Source Selection

Service: Selection of appropriate allogeneic cell lines (matched for specific HLAs) or harvesting autologous tumor cells from biopsy samples. Establishment of primary cell cultures.

Step 2: Genetic Engineering

Service: Viral (Lentivirus/Retrovirus) or non-viral (Electroporation) transduction of tumor cells to express cytokines (GM-CSF, IL-2) or costimulatory molecules (B7.1) to enhance immunogenicity.

Step 3: Expansion & Characterization

Service: Large-scale expansion of the modified cell lines. Characterization of transgene expression levels via Flow Cytometry and ELISA (for secreted cytokines).

Step 4: Lethal Irradiation

Service: Gamma-irradiation of the vaccine cells to arrest cell division (preventing tumor formation) while maintaining metabolic activity and antigen presentation capabilities.

Step 5: Preclinical Efficacy Study

Service: Vaccination of tumor-bearing mice. Evaluation of tumor growth inhibition, survival analysis, and immune profiling (T-cell infiltration, cytotoxicity assays).

Note: This workflow is strictly for preclinical research and development purposes.

Start Your Project

Advanced Technology Platforms

Our tumor cell vaccine solutions are supported by proprietary modification and analysis technologies:

High-efficiency Lentiviral and Retroviral vector systems designed for stable gene integration in difficult-to-transfect primary tumor cells. We offer ready-to-use vectors encoding common immunomodulators (GM-CSF, IL-12, B7.1).

High titer virus production
Multiple promoter options
Stable cell line generation

Gene editing platform to knockout immune checkpoint ligands (e.g., PD-L1, TGF-β) on the tumor vaccine cells, preventing them from suppressing the immune response at the vaccination site.

Precision gene knockout
Multiplex editing capabilities
Off-target analysis

A specialized Irradiation facility ensuring precise dosing to render cells replication-incompetent. We perform clonogenic survival assays to verify complete loss of proliferative capacity, a critical safety parameter.

Gamma irradiation
Apoptosis/Necrosis analysis
Metabolic activity assays (MTT)

Comprehensive immune monitoring services to assess the "Cross-Priming" effect. We track the uptake of vaccine antigens by host dendritic cells and the subsequent activation of tumor-specific CD8+ T cells.

In vitro cross-priming assays
Tetramer staining
ELISpot for IFN-γ

Viral Transduction

Gene Editing

Irradiation & Safety

Immune Monitoring

Inquire About Our Technology

Why Choose Creative Biolabs

Antigenic Breadth

Whole-cell approach targets multiple unknown antigens simultaneously, reducing tumor escape.

Engineering Expertise

Deep experience in modifying cells to express cytokines and costimulatory molecules.

Flexible Models

Solutions for both personalized Autologous and off-the-shelf Allogeneic vaccine strategies.

Combination Strategies

Expertise in designing combination studies with checkpoint inhibitors or chemotherapy.

Request a Free Consultation

Frequently Asked Questions

Q: What is the main advantage of using allogeneic vs. autologous tumor cells?

A: Autologous cells provide a perfect antigen match but are difficult to manufacture individually. Allogeneic cells serve as a "universal" off-the-shelf vaccine source, are easier to standardize and modify, and can induce an alloimmune response that may amplify the anti-tumor effect.

Q: Why is irradiation of the vaccine cells necessary?

A: Irradiation renders the tumor cells replication-incompetent, ensuring they cannot proliferate and form new tumors in the patient. Importantly, irradiated cells remain metabolically active for a period, continuing to secrete engineered cytokines and present antigens.

Q: How do you improve the immunogenicity of the tumor cell vaccine?

A: We employ several strategies, including genetic modification to express cytokines (like GM-CSF) that recruit dendritic cells, and expression of costimulatory molecules (like B7.1) to directly prime T cells. We can also combine the vaccine with adjuvants like BCG.

Q: What is the role of the HSCT platform in vaccine development?

A: High-dose therapy followed by Hematopoietic Stem Cell Transplantation (HSCT) creates a lymphopenic state. Vaccinating during the subsequent homeostatic expansion phase can skew the regenerating immune system towards tumor reactivity, potentially breaking tolerance to self-antigens.

Q: Can you develop vaccines for any cancer type?

A: Theoretically, yes. Since whole-cell vaccines use the tumor itself as the antigen source, they are applicable to a wide range of solid tumors and hematological malignancies. We have extensive experience with Prostate Cancer, Melanoma, and Leukemia models.

Ask Our Experts

Related Resources